AstraZeneca Announces Acquisition of Icosavax to Bolster Late-Stage Clinical Pipeline
Deal includes Icosavax’s protein virus-like particle platform technology, which could significantly improve treatments to protect against severe infectious diseases.
Image credit: Robert | stock.adobe.com
AstraZeneca has announced an agreement to acquire Icosavax, Inc, in a deal that could reach $1.1 billion. The acquisition of Icosavax, a clinical-stage biopharmaceutical company focused on vaccine development, is expected to bolster AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s protein virus-like particle (VLP) platform.1
Icosavax’s lead investigational candidate, IVX-A12, is a potential first-in-class, Phase III-ready, combination protein VLP vaccine being developed for both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
“This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV,” Iskra Reic, executive vice president, Vaccines & Immune Therapies, AstraZeneca, said in a press release. “With the addition of Icosavax’s Phase III-ready lead asset to our late-stage pipeline, we will have a differentiated, advanced investigational vaccine, and a platform for further development of combination vaccines against respiratory viruses. This aligns with our strategy to deliver a portfolio of therapies to address high unmet needs in infectious diseases, and our ambition to protect the most vulnerable patients who have high risk of severe outcomes.”1
Under the terms of the deal, AstraZeneca will acquire all of Icosavax’s outstanding shares for $15 per share in cash at closing, as well as a non-tradable contingent value right for up to $5 per share in cash if specific milestones are achieved. AstraZeneca’s upfront payment represents a premium of approximately 43% of Icosavax's closing market price on December 11, 2023. If all milestones are achieved, the upfront and maximum potential contingent value payments are approximately $1.1 billion.
The acquisition of the novel vaccine holds significance because there are currently no treatments or preventative therapies available for hMPV and no approved combination vaccines for RSV. IVX-A12 is the most advanced investigational vaccine targeting both RSV and hMPV and has a differentiated profile compared with RSV vaccines currently on the market, according to AstraZeneca. The liquid, refrigerator-stable formulation is comprised of IVX-121, an RSV prefusion F protein VLP vaccine candidate, and IVX-241, an hMPV prefusion F protein VLP vaccine candidate.
An ongoing, randomized, observer-blinded, placebo-controlled, multi-center Phase II trial is analyzing the safety and immunogenicity of a single dose of IVX-A12, with and without CSL Seqirus’ proprietary adjuvant MF59. Researchers enrolled 264 adults aged 60 to 85 years, of whom 241 were evaluable for immunogenicity.
Participants were administered a single dose of either IVX-A12 at the 300 µg combination dosage level (150 µg of RSV VLP (IVX-121) and 150 µg of hMPV VLP (IVX-241), with or without MF59, or placebo. The trial found that IVX-A12 produced robust immune responses against both RSV and hMPV at day 28 across both formulations with and without adjuvant.2 The FDA has awarded the novel vaccine with Fast Track Designation.
“We’re delighted to announce positive topline interim data from our Phase 2 trial of IVX-A12, our potential first-in-class combination vaccine candidate against RSV and hMPV,” Icosavax Chief Executive Officer Adam Simpson said in a press release.2 “We believe that IVX-A12 has the potential to address a significant unmet need and, as the furthest advanced RSV and hMPV combination vaccine in the clinic, to build on an emerging, large market opportunity.”
Icosavax’s pipeline also includes novel candidates as potential components for future combination and pan-respiratory vaccines, including influenza and SARS-CoV-2.1 AstraZeneca stated that the acquisition is expected to close in the first quarter of 2024.
“We are pleased to announce the proposed acquisition of Icosavax by AstraZeneca as we believe it offers the opportunity to accelerate, and expand access to, our potential first-in-class combination vaccine for older adults at risk of RSV and hMPV,” Simpson said in the release.1 “We look forward to combining our skills and expertise in advancing the development of IVX-A12 with AstraZeneca’s decades of experience in RSV, resources, and capabilities in late-stage development.”
References
1. AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data. AstraZeneca. News release. December 12, 2023. Accessed December 12, 2023. https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-icosavax-including-potential-first-in-class-rsv-and-hmpv-combination-vaccine-with-positive-phase-ii-data.html
2. Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults. Icosavax. News release. December 12, 2023. Accessed December 12, 2023. https://ir.icosavax.com/news-releases/news-release-details/icosavax-announces-positive-topline-interim-phase-2-results
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
